Skip to main content
OpenTrials
Completed

NCT Number: NCT00035282

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

The duration of treatment is 8 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients with Major Depressive Disorder

Treatment and study plan

Aprepitant

Drug

Other names: MK0869

Comparator: Placebo (Unspecified)

Drug

Primary outcomes

  1. HAMD-17 total score at week 8. Tolerability.

    Time frame: at week 8

Secondary outcomes

  1. CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8

    Time frame: at week 8

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder

Important dates

Study start
2001
Primary completion
2003
Study completion
2003
First posted
May 3, 2002
Registry last updated
Feb 9, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.